IONIS PHARMACEUTICALS, INC. (NASDAQ:IONS) Files An 8-K Other Events
Item 8.01
|
Other Events.
|
a press release announcing that the Phase 3 NEURO-TTR study of
inotersen (IONIS-TTRRx) in patients with familial
amyloid polyneuropathy (FAP) met both primary endpoints.
Current Report and incorporated herein by reference.
| Item 9.01. |
Financial Statements and Exhibits.
|
| 99.1 |
Press Release dated May 15, 2017.
|
About IONIS PHARMACEUTICALS, INC. (NASDAQ:IONS)
Ionis Pharmaceuticals, Inc., formerly Isis Pharmaceuticals, Inc., is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company’s Ionis Core segment is developing a drug discovery platform. The Company’s Akcea Therapeutics segment consists of the operations of its subsidiary, Akcea Therapeutics, Inc., which develops and commercializes drugs for cardiometabolic disorders. The Company is developing transformational drugs, which include nusinersen, IONIS-TTR and volanesorsen that are designed to treat patients with orphan diseases. In addition to its Phase III programs, the Company has a pipeline of drugs in Phase II development, which includes IONIS-FXI and IONIS-APO(a)-L. Its Phase II pipeline includes drugs to treat patients with severe and rare diseases, viral infections, ocular diseases, metabolic disorders and cardiovascular diseases. IONIS PHARMACEUTICALS, INC. (NASDAQ:IONS) Recent Trading Information
IONIS PHARMACEUTICALS, INC. (NASDAQ:IONS) closed its last trading session down -1.78 at 43.16 with 1,581,890 shares trading hands.
